- Details
- Alicia Morgans hosts a discussion with Professors Silke Gillessen and Aurelius Omlin about the upcoming APCCC 2024, emphasizing its significance for the prostate cancer community. The congress invites all interested in prostate cancer management, offering a blend of clinical and translational research insights. The conversation also touches on the congress's inclusivity, encouraging participation...
|
- Details
- Zach Klaassen and Alexander Cole discuss the impact of climate change on cancer screening, highlighting a study that explores public awareness of climate change's health impacts and its association with cancer risk attitudes. Utilizing the HINTS database, they found a correlation between concern for climate change and interest in cancer screening, suggesting that awareness of environmental health...
|
- Details
- Zach Klaassen and Ryan Malone discuss the management of Nonmetastatic castration-resistant prostate cancer (nmCRPC), focusing on the evolving role of PSMA PET imaging. They highlight the importance of defining PSA progression and the challenges posed by new imaging techniques in identifying low-volume disease. The discussion covers landmark trials and their implications for treatment options, emph...
|
- Details
- Andrea Miyahira and Alex Wyatt discuss a study on de novo metastatic prostate cancer, revealing its genomic complexity through multiregion sampling. Published in Nature Cancer, the research highlights the polyclonality of the disease and its implications for clinical genotyping. By examining multiple regions from patients' prostates and lymph nodes, the study uncovers significant genomic heterogen...
|
- Details
- Andrea Miyahira hosts Andrew Goldstein to discuss his group's research on prostate cancer, published in Nature Cell Biology. Dr. Goldstein, along with his team, including grad students Jenna Giafaglione and Preston Crowell, explores the metabolic processes influencing prostate cancer's response to anti-androgen treatment. Their study reveals that basal and luminal cells in the prostate have distin...
|
- Details
- Andrea Miyahira hosts Johann De Bono to discuss his group's paper on reversing prostate cancer therapy resistance by targeting myeloid chemotaxis. Dr. De Bono, with contributions from his team, including Christina Guo and Adam Sharp, explores the role of inflammation in prostate cancer. The study focuses on how stressed cancer cells attract inflammatory cells, which can then support tumor growth a...
|
- Details
- Andrea Miyahira hosts Ping Mu to discuss his group's research on prostate cancer resistance to anti-androgens. Dr. Mu's study, published in Oncogene, focuses on the gene UBE2J1, identified as a key E2 ubiquitin-conjugating enzyme regulating Androgen Receptor (AR) degradation. He explains that despite advancements in anti-androgen therapies like enzalutamide, resistance remains a significant challe...
|
- Details
- We conducted a study to assess the safety and efficacy of relugolix combined with abiraterone acetate or apalutamide. We presented results from this ongoing, two-part, Phase I, 52-week, open-label cohort study in patients with advanced prostate cancer (NCT04666129), which evaluated relugolix in combination with abiraterone acetate and a corticosteroid (prednisone or methylprednisolone) in Part 1,...
|
- Details
- Andrea Miyahira interviews Mayuko Kanayama about her team's research on a HOXB13 variant linked to aggressive prostate cancer in African ancestry populations. Published in European Urology, their study focuses on the HOXB13 stop-loss germline variant X285K, prevalent in West African ancestry, including Nigeria, Senegal, and Ghana. This variant, associated with earlier diagnosis and higher Gleason...
|
- Details
- Asmaa El-Kenawi discusses her group's research on therapeutic resistance in cancer, particularly focusing on the role of methionine in driving resistance. Published in "Cancer Research," the study explores how cancer cells adapt to evade pyroptosis, a form of cell death. Dr. El-Kenawi, an assistant professor at Indiana University, explains that while many effective cancer therapies exist, resistan...
|
